Effect of esomeprazole versus famotidine on platelet inhibition by clopidogrel: A double-blind, randomized trial

American Heart Journal

Volumn 162, Issue 5, 2011, Pages 870-874

  Tunggal, Prabowo ^a   Ng, Fook Hong ^a   Lam, Kwok Fai ^b   Chan, Francis K L ^c   Lau, Yuk Kong ^a  

^a RUTTONJEE HOSPITAL   (Hong Kong)

^b UNIVERSITY OF HONG KONG   (Hong Kong)

^c CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; ESOMEPRAZOLE; FAMOTIDINE;

ACUTE CORONARY SYNDROME; ADULT; AGED; ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DUODENUM ULCER; FEMALE; FOLLOW UP; HUMAN; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STOMACH EROSION; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION INHIBITION; UPPER GASTROINTESTINAL BLEEDING;

ACUTE CORONARY SYNDROME; ANTI-ULCER AGENTS; BLOOD PLATELETS; DOUBLE-BLIND METHOD; FAMOTIDINE; FEMALE; HUMANS; MALE; MIDDLE AGED; OMEPRAZOLE; PLATELET AGGREGATION INHIBITORS; PROSPECTIVE STUDIES; TICLOPIDINE; TREATMENT OUTCOME;

EID: 81255214744     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2011.08.007     Document Type: Article

References (32)

1. S. Yusuf, F. Zhao, and S.R. Mehta Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation N Engl J Med 345 2001 494 502 (Pubitemid 32758501)
2. Z.M. Chen, L.X. Jiang, and Y.P. Chen Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomized placebo-controlled trial Lancet 366 2005 1607 1621
3. J.L. Anderson, C.D. Adams, and E.M. Antman ACC/AHA 2007 guidelines for the management of patients with unstable angina/non ST-elevation myocardial infarction Circulation 116 2007 803 877
4. E.M. Antman, M. Hand, and P.W. Armstrong 2007 Focused update of the ACC/AHA 2004 guidelines for the management of patients with ST-Elevation myocardial infarction Circulation 117 2008 296 329
5. S.R. Mehta, S. Yusuf, and R.J.G. Peters Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study Lancet 358 2001 527 533 (Pubitemid 32772726)
6. S.V. Manoukian, F. Feit, and R. Mehran Impact of major bleeding on 30-day mortality and clinical outcomes in patients with acute coronary syndromes: an analysis from the ACUITY Trial J Am Coll Cardiol 19 2007 1362 1368 (Pubitemid 46476844)
7. S.V. Rao, K. O'Grady, and K.S. Pieper A comparison of the clinical impact of bleeding measured by two different classifications among patients with acute coronary syndromes J Am Coll Cardiol 47 2006 809 816 (Pubitemid 43243106)
8. M.W. Chin, G. Yong, and M.K. Bulsara Predictive and protective factors associated with upper gastrointestinal bleeding after percutaneous coronary intervention: a case-control study Am J Gastroenterol 102 2007 2411 2416 (Pubitemid 47631776)
9. F.H. Ng, S.Y. Wong, and K.F. Lam Gastrointestinal bleeding in patients receiving a combination of aspirin, clopidogrel, and enoxaparin in acute coronary syndrome Am J Gastro 103 2008 865 871
10. M. Luinstra, M. Naunton, and G.M. Peterson PPI use in patients commenced on clopidogrel: a retrospective cross-sectional evaluation J Clin Pharm 35 2010 213 217
11. D.L. Bhatt, B. Cryer, and C.F. Contant Clopidogrel with or without omeprazole in coronary artery disease N Engl J Med 363 2010 1909 1917
12. N.S. Abraham, M.A. Hlatky, and E.M. Antman ACCF/ACG/AHA 2010 expert consensus document on the concomitant use of proton pump inhibitors and thienopyridines: a focused update of the ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use. A report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents J Am Coll Cardiol 56 2010 2051 2066
13. E. Pezalla, D. Day, and I. Pulliadath Initial assessment of clinical impact of a drug interaction between clopidogrel and proton pump inhibitors JACC 52 2008 1038 1039
14. D.N. Juurlink, T. Gomes, and D.T. Ko A population-based study of the drug interaction between proton pump inhibitors and clopidogrel CMAJ 180 2009 713 718
15. P.M. Ho, T.M. Maddox, and L. Wang Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome JAMA 301 2009 937 944
16. K.M. Stockl, L. Le, and A. Zakharyan Risk of rehospitalization for patients using clopidogrel with a proton pump inhibitor Arch Intern Med 170 2010 704 710
17. M.A. Gaglia Jr, R. Torguson, and N. Hanna Relation of proton pump inhibitor use after percutaneous coronary intervention with drug-eluting stents to outcomes Am J Cardiol 105 2010 833 838
18. M. Gilard, B. Arnaud, and J.C. Cornily Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin. The OCLA Study J Am Coll Cardiol 51 2008 256 260
19. J.M. Siller-Matula, A.O. Spiel, and I.M. Lang Effects of pantoprazole and esomeprazole on platelet inhibition by clopidogrel Am Heart J 157 2009 148.e1 148.e5
20. Food and Drug Administration. Early Communication about an Ongoing Safety Review of Clopidogrel Bisulfate (marketed as Plavix) and Omeprazole (marketed as Prilosec and Prilosec OTC). November 17, 2009. Available from: http://www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsandProviders/ DrugSafetyInformationforHeathcareProfessionals/ucm190784.htm.
21. Food and Drug Administration. Information for Healthcare Professionals: Update to the labeling of clopidogrel bisulfato (marketed as Plavix) to alert healthcare professionals about a drug interaction with omeprazole (marketed as Prilosec and Prilosec OTC). [17 November 2009]. Free access on: http://www.fda.gov/Safety/MedWatch/SafetyInformation/ SafetyAlertsforHumanMedicalProducts/ucm190848.htm.
22. F.H. Ng, K.F. Lam, and S.Y. Wong Upper gastrointestinal bleeding in patients with aspirin and clopidogrel co-therapy Digestion 77 2008 173 177
23. A. Lanas, E. Bajador, and P. Serrano Nitrovasodilators, low-dose aspirin, other nonsteroidal anti-inflammatory drugs, and the risk of upper gastrointestinal bleeding N Engl J Med 343 2000 834 839
24. T.J. Humphries Famotidine: a notable lack of drug interactions Scand J Gastroenterol Suppl 134 1987 55 60 (Pubitemid 17112439)
25. G. Patti, A. Nusca, and F. Mangiacapra Point-of-care measurement of clopidogrel responsiveness predicts clinical outcome in patients undergoing percutaneous coronary intervention J Am Coll Cardiol 52 2008 1128 1133
26. C.Y. Wu, F.K. Chan, and M.S. Wu Histamine2-receptor antagonists are an alternative to proton pump inhibitor in patients receiving clopidogrel Gastroenterology 139 2010 1165 1171
27. N. von Beckerath, G. Pogatsa-Murray, and A. Wieczorek Correlation of a new point-of-care test with conventional optical aggregometry for the assessment of clopidogrel responsiveness Thromb Haemost 95 2006 910 911
28. M.J. Price, S. Endemann, and R.R. Gollapudi Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation E Heart J 29 2008 992 1000 (Pubitemid 351844676)
29. S.P. Dunn, T.E. Macaulay, and D.M. Brennan Baseline proton pump inhibitor use is associated with increased cardiovascular events with and without the use of clopidogrel in the CREDO trial Circulation 118 2008 S815
30. J.A. Rassen, N.K. Choudhry, and J. Avorn Cardiovascular outcomes and mortality in patients using clopidogrel with proton pump inhibitors after percutaneous coronary intervention or acute coronary syndrome Circulation 120 2009 2322 2329
31. M.L. O'Donoghue, E. Braunwald, and E.M. Antman Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton pump inhibitor: an analysis of two randomized trials Lancet 374 2009 989 997
32. W.A. Ray, K.T. Murray, and M.R. Griffin Outcomes with concurrent use of clopidogrel and proton pump inhibitors Ann Intern Med 152 2010 337 345